Biocodex renews its partnership with Future4care to continue accelerating innovation in digital health

Future4care, the European ecosystem dedicated to digital health, is proud to announce the renewal of its strategic partnership with Biocodex, an independent pharmaceutical company, a pioneer in the microbiome field, and committed to patient-centered innovation. This renewal continues a rich and fruitful collaboration that began in 2022, marked by Biocodex’s active contribution to the Future4care ecosystem.

Since 2022, the partnership between Biocodex and Future4care has led to numerous tangible initiatives: Biocodex’s active involvement with Future4care member startups (including an equity investment in GMT Science, a gut microbiome analysis startup), the development of patient-centered projects—particularly in the fields of rare diseases, women’s health, and the microbiome—and training for employees in artificial intelligence through the Future4care Academy.

Biocodex has also taken an active part in key moments of the ecosystem, such as the GenAI Festival and Demo Days, and has engaged in Open Innovation through Learning Expeditions and workshops dedicated to sustainability challenges.

"The partnership with Biocodex perfectly illustrates our ambition to bring together leading players in their fields to unite forces in accelerating transformation in the health sector. We are thrilled with this renewal, which marks a new stage in our collaboration to bring concrete solutions to life for the benefit of patients. We thank the Biocodex teams for their trust", said Agnès de Leersnyder, CEO of Future4care.

"This renewal fully aligns with our vision of meaningful innovation, rooted in the realities of patients and healthcare professionals. Alongside Future4care, we continue our commitment to developing concrete solutions where needs and expectations remain high."
Nicolas Coudurier, CEO of Biocodex

This renewal opens a new phase in the partnership between Biocodex and Future4care, firmly focused on impact and the innovation of tomorrow. Together, we continue to create synergies to accelerate the development of solutions in key areas such as the microbiome, rare diseases, and women’s health. We share a European vision of digital health and are jointly committed to collective innovation, One Health, and the adoption of artificial intelligence.

Our common goal is to bring to life innovations that are useful, ethical, and truly centered on the needs of patients and healthcare professionals.

About Biocodex
Biocodex is an independent, family-owned French pharmaceutical company founded in 1953. It is committed to improving patients’ health and well‑being at every stage of life through three core pillars: gut microbiota, women’s health, and orphan diseases. Biocodex is the manufacturer of Saccharomyces boulardii CNCM I‑745, a pioneering probiotic strain and the current global leader in value in its category.

About Future4care

Future4care is a European ecosystem of multidisciplinary players dedicated to digital health. A joint venture founded in 2021 by the alliance of Capgemini, Generali, Orange and Sanofi, Future4care brings together E-health players (major groups, experts, healthcare professionals, startups, etc.) to create synergies and opportunities that will accelerate progress in digital healthcare. Since its launch, Future4care has brought together industrial and institutional partners, as well as qualified personalities from the scientific and cademic worlds within a Scientific and Ethical Council.